Adalimumab for the treatment of juvenile idiopathic arthritis
|
Status
|
Discontinued
|
|
Decision
|
Selected
|
| Process |
TA
|
| Referral date |
01 June 2008 |
|
Topic area
|
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
Project Team
| Communications manager: |
TBC |
| Executive Lead: |
TBC |
| Project manager: |
TBC |
| Technical Lead: |
TBC |
|
Date
|
Update
|
|
1 July 2011
|
Following on from the licence extension for adalimumab for juvenile idiopathic arthritis an additional draft scope consultation was conducted in November 2010. As a result of the consultation this topic will not be re referred onto the technology appraisals work programme. Please see the Block Scoping Report for further information |
|
23 December 2008
|
Please note that this topic has been removed from the technology appraisals work programme. |
|
22 September 2008
|
The above topic was referred to NICE as part of the 17th wave referrals. Following an update on the anticipated licence for adalimumab in this therapeutic area, limiting the use of this drug to a small population with juvenile idiopathic arthritis, we have concluded that further discussions with the Department of Health are required to establish how best to progress this appraisal.
We are therefore suspending this single technology appraisal whilst we consider the next steps. Please be assured that we will update you with further information once we have finalised our discussions. |
For further information on our processes and methods, please see our CHTE processes and methods manual